Margot NA - Search Results

1

Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.

Margot NA, Naik V, VanderVeen L, Anoshchenko O, Singh R, Dvory-Sobol H, Rhee MS, Callebaut C. Margot NA, et al. J Infect Dis. 2022 Nov 28;226(11):1985-1991. doi: 10.1093/infdis/jiac364. J Infect Dis. 2022. PMID: 36082606

2

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M. Miller MD, et al. J Infect Dis. 2004 Mar 1;189(5):837-46. doi: 10.1086/381784. Epub 2004 Feb 10. J Infect Dis. 2004. PMID: 14976601 Clinical Trial.

3

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.

Margot NA, Johnson A, Miller MD, Callebaut C. Margot NA, et al. Antimicrob Agents Chemother. 2015 Oct;59(10):5917-24. doi: 10.1128/AAC.01151-15. Epub 2015 Jul 6. Antimicrob Agents Chemother. 2015. PMID: 26149983 Free PMC article.

4

Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.

Margot NA, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C. Margot NA, et al. HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731. HIV Clin Trials. 2016. PMID: 26892863 Clinical Trial.

5

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.

Margot NA, Liu Y, Miller MD, Callebaut C. Margot NA, et al. Antiviral Res. 2016 Aug;132:50-8. doi: 10.1016/j.antiviral.2016.05.012. Epub 2016 May 18. Antiviral Res. 2016. PMID: 27208653

6

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.

Margot N, Cox S, Das M, McCallister S, Miller MD, Callebaut C. Margot N, et al. Antivir Ther. 2017;22(5):443-446. doi: 10.3851/IMP3125. Epub 2017 Jan 11. Antivir Ther. 2017. PMID: 28076335

7

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, Miller MD. Abram ME, et al. Among authors: margot na. PLoS One. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206. eCollection 2017. PLoS One. 2017. PMID: 28212411 Free PMC article.

8

Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.

Cox S, Margot N, Ram R, Johnson A, Miller M, Callebaut C. Cox S, et al. Antiviral Res. 2017 Jul;143:22-29. doi: 10.1016/j.antiviral.2017.03.021. Epub 2017 Mar 28. Antiviral Res. 2017. PMID: 28363735

9

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.

Margot NA, Wong P, Kulkarni R, White K, Porter D, Abram ME, Callebaut C, Miller MD. Margot NA, et al. J Infect Dis. 2017 Mar 15;215(6):920-927. doi: 10.1093/infdis/jix015. J Infect Dis. 2017. PMID: 28453836

10

Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R.

Cox S, Margot N, Miller M, Callebaut C. Cox S, et al. AIDS Res Hum Retroviruses. 2018 May;34(5):456-458. doi: 10.1089/AID.2017.0248. Epub 2018 Apr 10. AIDS Res Hum Retroviruses. 2018. PMID: 29620930

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters